The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
BACE inhibition-dependent repair of Alzheimer’s pathophysiology
Open accessAbstract
Significance The accumulation of amyloid-β (Aβ) proteins in the brain contributes to Alzheimer´s disease (AD). Reducing Aβ by inhibiting its production with a β-secretase (BACE) inhibitor represents a novel mechanism for treating AD; however, whether this therapeutic strategy is capable of repairing impaired brain circuits associated with AD is unknown. Here we demonstrate that BACE inhibition is beneficial to all levels of impairment in an AD mouse model: cellular, long-range circuitry, and memory. We provide evidence that the rescue is dependent on the reduction of soluble forms of Aβ surrounding amyloid plaques. These results have mechanistic and therapeutic implications for AD, including Aβ-related memory defects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which has been shown to be dependent on soluble Aβ [38–40]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [38]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“NB-360 inhibits the enzymatic activity of BACE, which is required for the generation of Aβ peptides from APP (12).”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651
Cited by
Sorted by citations
Items 101–126 of 126
Lee, S., Kim, J. C., Choi, M., Song, J., Kim, M., Chang, S.-H., Kim, J. S., Park, J.-S., & Lee, S.-R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210942 · Cited by 3
The Value of the Object Recognition Paradigm in Investigating Animal Models of Alzheimer's Disease
Mathis, C. (2018) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-812012-5.00021-5 · Cited by 3
Singh, S., Kushwaha, V., Sisodia, S., Kumar, S., & Sahu, K. K. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249315049240710063455 · Cited by 3
Deletion of Dcf1 Reduces Amyloid-β Aggregation and Mitigates Memory Deficits
Li, W., Gan, L., Ma, F.-F., Feng, R., Wang, J., Li, Y., Sun, Y., Wang, Y.-J., Diao, X., Qian, F.-Y., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200619 · Cited by 4
Bruña, R., Maestú, F., López‐Sanz, D., Bagic, A. I., Cohen, A. D., Chang, Y., Cheng, Y., Doman, J. M., Huppert, T., Kim, T., et al. (2021) · Brain Connectivity · doi:10.1089/brain.2021.0059 · Cited by 3
Pomara, N., & Bruno, D. (2018) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180077 · Cited by 3
Pre-therapeutic Microglia Activation and Sex Determine Therapy Effects of Chronic ImmunomodulationPreprint
Biechele, G., Blume, T., Deußing, M., Zott, B., Shi, Y., Xiang, X., Franzmeier, N., Kleinberger, G., Peters, F., Ochs, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.30.445761 · Cited by 3
Self-citationVolloch, V. (2019) · Preprints.org · doi:10.20944/preprints201902.0172.v1 · Cited by 3
McGregor, J. N., Farris, C. A., Ensley, S., Schneider, A. M., Wang, C., Liu, Y., Tu, J., Elmore, H., Ronayne, K. D., Weßel, R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.01.555947 · Cited by 3
Volloch, V., & Rits‐Volloch, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189913 · Cited by 3
Volloch, V., & Rits‐Volloch, S. (2025) · Genes · doi:10.3390/genes16010046 · Cited by 3
Imbimbo, B. P., & Pomara, N. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0013 · Cited by 2
Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves CognitionPreprint
Blume, T., Deußing, M., Biechele, G., Peters, F., Zott, B., Schmidt, C., Franzmeier, N., Wind-Mark, K., Eckenweber, F., Sacher, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.30.446348 · Cited by 2
Self-citationA mechanistic model explains oscillatory slowing and neuronal hyperactivity in Alzheimer’s diseasePreprint
Alexandersen, C. G., de Haan, W., Bick, C., & Goriely, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.20.496731 · Cited by 2
Volloch, V., & Rits‐Volloch, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094252 · Cited by 3
Amyloid β–dependent neuronal silencing through synaptic decoupling
Zhang, Y., Chen-Engerer, H.-J., Zhang, K., Zott, B., Varga, Z., Chen, Y., Chen, X., Hongbo, J., Sakmann, B. J., Nelken, I., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515113122 · Cited by 2
Self-citationMeftah, S., Kang, S., Liu, M., Wang, X., Topçu, A. N., Abad, M., Kőszeghy, Á., Wan, L., Mullin, C., Zoupi, L., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09918-y · Cited by 2
Faculty Opinions recommendation of A vicious cycle of β amyloid-dependent neuronal hyperactivation.
Hell, J. W. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736365538.793564339 · Cited by 1
Volloch, V. (2019) · Preprints.org · doi:10.20944/preprints201902.0172.v3
Wang, J., Liu, B., Xu, Y., Wang, C.-Y., Yang, M.-Z., Song, M., Liu, J., You, J., Sun, F., Wang, W.-T., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-126764/v1
Volloch, V. (2019) · Preprints.org · doi:10.20944/preprints201902.0172.v4
Modelling the contributions to hyperexcitability in a mouse model of Alzheimer’s diseasePreprint
Mittag, M., Mediavilla, L., Remy, S., Cuntz, H., & Jedlička, P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.29.494500
Scheijbeler, E. P., de Haan, W., Stam, C. J., Twisk, J. W. R., & Gouw, A. A. (2023) · Figshare · doi:10.6084/m9.figshare.24406679
Scheijbeler, E. P., de Haan, W., Stam, C. J., Twisk, J. W. R., & Gouw, A. A. (2024) · Figshare · doi:10.6084/m9.figshare.24406887
Metadata
- Authors
- Keskin, A. D., Kekuš, M., Adelsberger, H., Neumann, U., Shimshek, D. R., Song, B., Zott, B., Peng, T., Förstl, H., Staufenbiel, M., Nelken, I., Sakmann, B., Konnerth, A., & Busche, M. A.
- Affiliations
- Technical University of Munich (DE)
- Novartis (Switzerland) (CH)
- Helmholtz Munich (DE)
- Hertie Institute for Clinical Brain Research (DE)
- Hebrew University of Jerusalem (IL)
- Munich Cluster for Systems Neurology (DE)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-07-24
- Volume
- 114
- Issue
- 32
- Pages
- 8631-8636
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5559049
- OpenAlex
- W2738200982
- Cited by
- 125
- References
- 44
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 19 · 2023: 11 · 2022: 10 · 2021: 19 · 2020: 13 · 2019: 28 · 2018: 13
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- EC | FP7 | FP7 Ideas: European Research Council (Advanced Grant)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, beta-secretase inhibitors, amyloid-beta, amyloid plaques, soluble amyloid-beta, memory impairment, AD mouse model
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Humans, Mice, Transgenic, Neurons, Protease Inhibitors, Amyloid beta-Peptides, Mice, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
